A phase I clinical trial is currently underway to evaluate the feasibility of using [89Zr]Zr-DFO-avelumab to assess PD-L1 expression in patients with NSCLC and whether prediction of avelumab treatment response is possible (NCT03514719, PINNACLE). The gene discussed is CD274; the disease is non-small cell lung carcinoma.